Stock DTIL PRECISION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
9.73 USD +3.29% Intraday chart for Precision BioSciences, Inc. +3.51% -11.14%
06-12 Transcript : Precision BioSciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM
06-05 Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
BU
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
BU
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
BU
Precision BioSciences to Participate in Upcoming June Investor Conferences
BU
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4)
AQ
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
Precision BioSciences: Q1 Earnings Snapshot
AQ
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
BU
Precision BioSciences to Report First Quarter Results on May 13, 2024
BU
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
BU
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
BU
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
BU
Precision BioSciences: Q4 Earnings Snapshot
AQ
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
BU
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
BU
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
BU
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506
AQ
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
BU
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DTIL Stock
  4. News Precision BioSciences, Inc.
  5. Press Releases